Dibenedetto, S P
Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. [electronic resource]
- Blood Aug 1997
- 1226-32 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
ISSN: 0006-4971
Subjects--Topical Terms: Adolescent Antineoplastic Combined Chemotherapy Protocols--therapeutic use Asparaginase--administration & dosage Biomarkers, Tumor--analysis Blotting, Southern--methods Bone Marrow--pathology Child Child, Preschool Cohort Studies Cyclophosphamide--administration & dosage Cytarabine--administration & dosage DNA, Neoplasm--analysis Daunorubicin--administration & dosage Disease-Free Survival Evaluation Studies as Topic Female Fluorometry Gene Rearrangement, delta-Chain T-Cell Antigen Receptor Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor Humans Immunophenotyping Infant Italy--epidemiology Leucovorin--administration & dosage Leukemia-Lymphoma, Adult T-Cell--drug therapy Male Mercaptopurine--administration & dosage Methotrexate--administration & dosage Neoplasm, Residual Neoplastic Stem Cells--chemistry Nucleic Acid Hybridization--methods Polymerase Chain Reaction--methods Prednisone--administration & dosage Prognosis Prospective Studies Receptors, Antigen, T-Cell, gamma-delta--analysis Remission Induction Sensitivity and Specificity Treatment Outcome Vincristine--administration & dosage